Loading stock data…
$21.01-0.05 (-0.24%)
Fulgent Genetics, Inc.
Fulgent Genetics, Inc. in the Healthcare sector is trading at $21.01 with a market capitalization of $512M. Wall Street consensus targets $19.00 (1 analysts), implying a -9.6% move over the next 12 months. The stock is currently 32% below its 52-week high of $31.04, remaining 6.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $85.39M↑ | $71.14M↓ | $83.34M↓ | $84.07M↑ | $81.80M |
| Gross Profit | $25.68M↑ | $21.49M↓ | $32.58M↓ | $35.51M↑ | $34.44M |
| Operating Income | -$33.90M↑ | -$34.62M↑ | -$36.24M↓ | -$15.35M↑ | -$19.71M |
| Net Income | -$29.53M↓ | -$24.83M↓ | -$23.42M↓ | -$6.61M↑ | -$18.96M |
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic t...